Focus on gastric cancer  by Ushijima, Toshikazu & Sasako, Mitsuru
CANCER CELL : FEBRUARY 2004 · VOL. 5 · COPYRIGHT © 2004 CELL PRESS 121
Epidemiology and incidence statistics
Gastric cancer is the second most common cancer in the world
(Ferlay et al., 2001). It is unique in that its time trend and geo-
graphical distribution are very informative in estimating its risk
factors. In the US, the crude mortality rate in Caucasian males
was 33/100,000 in the early 20th century, and this declined to
5/100,000 in the late 20th century. The declining trend is world-
wide, and the decline began earlier in developed countries.
However, even among them, mortality is still high in Korea
(43/100,000), Russia (35/100,000), Japan (31/100,000), and
Portugal (22/100,000). The age-adjusted incidence reaches as
high as 70/100,000 in Korean and Japanese males.The male to
female ratio is consistently two to one in many geographical
regions.
The decline took place following the popularization of refrig-
erators, which resulted in a decreased intake of salt and an
increased intake of fruit and vegetables (Palli, 2000; Potter et
al., 1997). The preventive effects of fruit and vegetables are
consistently confirmed by many epidemiological studies. Most
epidemiological studies have shown the promoting effect of salt
and the preventive effect of vitamin C. The effects of salt were
also shown by animal experiments. Some epidemiological stud-
ies suggest that consumption of grilled meat/fish increases the
risk, and that the consumption of carotenoids and green tea
reduce the risk. Epidemiological data linking N-nitrosamines to
gastric cancers have so far been inconclusive, although their
carcinogenicity at high doses is proven.
Infection by Helicobacter pylori is prevalent in areas with
high incidences of gastric cancers, and increases the risk of
gastric cancer. However, in some Asian countries, such as India
and Thailand, incidences of gastric cancers are not high in spite
of the high H. pylori infection rates, a phenomenon known as the
“Asian Enigma” (Miwa et al., 2002). Possible explanations for
this include host genetic factors, different virulence among
strains of H. pylori, and dietary factors. Polymorphisms of proin-
flammatory cytokine genes have been shown to associate with
risk of H. pylori-related gastric cancers (El-Omar et al., 2000).
Animal models
A rat model for gastric cancers induced by a chemical carcino-
gen, N-methyl-N’-nitro-N-nitrosoguanidine, has been widely
used for a variety of purposes, such as evaluation of various
promoting and preventing factors and clarification of genes
involved in genetic susceptibility (Yamashita et al., 2002). A
model in which H. pylori could infect an animal was established
using Mongolian gerbils, which contributed to clarification of the
strong promoting effect of H. pylori (Shimizu et al., 1999).
In addition, there have been more than 10 lines of genetical-
ly modified mice that show hyperplasia of the gastric epithelium
and/or intestinal metaplasia (Gut et al., 2002). These mouse
models were created by targeting genes involved in ion trans-
port, signal transduction, transcriptional regulation, and cell
adhesion. Development of gastric cancers was observed in
mice lacking the pS2 trefoil protein, those lacking Smad4/Dpc4,
those lacking the SHP2 binding site on the Il-6 family corepres-
sor gp130, and those lacking RUNX3 (Judd et al., 2004;
Lefebvre et al., 1996; Xu et al., 2000; Li et al., 2002).
Disease mechanism and molecular targets
Histological classification and gastric /intestinal
phenotypes
Histological classification of gastric cancers is different between
Japan and Western countries. Generally, “differentiated” and
“undifferentiated” types in Japanese classification correspond
to “intestinal” and “diffuse” types, respectively, in the Western
classification established by Lauren. It has been considered
that intestinal-type gastric cancers are associated with intesti-
nal metaplasia, whereas diffuse-type gastric cancers are origi-
nated from gastric mucosa proper. Recent analysis of gastric
and intestinal phenotypes in early gastric cancers has shown
that cancer cells with gastric phenotypes were present in both
intestinal and diffuse types of gastric cancer. Furthermore, phe-
notypic expression in gastric cancer cells was shown to be inde-
pendent of phenotypic changes in the surrounding gastric
mucosa (Tatematsu et al., 2003).
Gastric cancer predisposition
Germline mutations of E-cadherin were first found in a large
family from New Zealand in which diffuse-type gastric cancers
took place at an early age (Guilford et al., 1998). Although E-
cadherin germline mutations are very rare, the finding provided
to be useful information for clinicians to manage high-risk
patients. Gastric cancers, mainly of the intestinal type, can be
associated with hereditary nonpolyposis colorectal cancer
(HNPCC) syndrome, most cases of which are caused by
germline mutations of mismatch repair genes hMLH1 or
hMSH2, and are more prominently manifested in older genera-
tions of HNPCC patients. Patients with familial adenomatous
polyposis, which is caused by germline mutations of APC, and
Peutz-Jeghers syndrome also have increased risk for gastric
cancer (Oberhuber and Stolte, 2000).
Molecular alterations in gastric cancer
Many genes have been analyzed in attempts to understand the
molecular bases for human gastric cancers, but only a few with
frequent alterations have been identified (Table 1). Oncogenic
activations of β-catenin (17%–27% in intestinal type) and K-ras
(0%–18% in both histological types) have been found in human
gastric cancers (Lee et al., 2002; Park et al., 1999). In addition,
amplifications of the c-erbB2 and the c-met genes have each
been found in approximately 10% of both histological types.
As for tumor-suppressor genes, p53 mutations are repeat-
edly reported in gastric cancers of the diffuse type (0%–21%)
and intestinal type (36%–43%) (Maesawa et al., 1995).
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Mutations of the APC tumor suppressor gene are found fre-
quently in gastric adenomas, but only rarely in gastric cancers;
this is clearly different from the similar frequencies of APC
mutations in colorectal adenomas and carcinomas (Lee et al.,
2002; Maesawa et al., 1995). Somatic mutations of E-cadherin
are observed specifically in sporadic diffuse-type gastric can-
cers (33%–50%) (Becker et al., 1994). RUNX3 was recently
shown to be a tumor-suppressor gene of gastric cancers,
although its mutations were rare (Li et al., 2002).
Microsatellite instability (MSI) is observed in 5%–10% of dif-
fuse-type gastric cancers and in 15%–40% of intestinal-type
gastric cancers. The major mechanism for the MSI in gastric
cancer is inactivation of the mismatch repair gene hMLH1
resulting from hypermethylation of its promoter (Fang et al.,
2003). Similarly, mutation of the p16 gene is infrequent, but
hypermethylation of p16 is common (25%–42% overall) in gas-
tric cancer, with the intestinal type having higher incidence
(Ding et al., 2003; Oue et al., 2002).
Factors that induce molecular alterations
Although hMLH1 and p16 can be inactivated in gastric cancers
by mutations or by promoter hypermethylation, inactivation by
methylation is much more frequent than mutation in sporadic
gastric cancers.The second hit in E-cadherin germline mutation
carriers is also generally due to methylation (Machado et al.,
2001). A genome-wide scan for aberrant methylations revealed
silencing of nine genes in gastric cancers (Kaneda et al., 2002).
Even in noncancerous gastric mucosae (Waki et al., 2002),
aberrant methylation can be present. These findings suggest
that aberrant methylation is deeply involved in gastric carcino-
genesis, and aberrant methylation seems to be useful as a new
target for diagnostics and prevention of gastric cancers.
The presence of Epstein-Barr virus (EBV) is observed in
7%–20% of gastric cancers, being slightly more frequent in dif-
fuse-type gastric cancers. EBV is clonal in cancer tissue, and is
maintained as a plasmid. EBV has been shown to extend cell
generations of gastric epithelial cells in in vitro cell culture, but it
cannot immortalize them (Takada, 2000). Recently, EBV-associ-
ated gastric cancers were shown to be more frequently
associated with promoter methylation of p16 (Kang et al., 2002).
There has been discussion about whether intestinal meta-
plasia (IM) is a precancerous lesion for gastric cancers.
Although gastric cancers are frequently accompanied by IM, no
molecular alterations that cause both IM and gastric cancers
have been identified. It is thus more likely that factors that
induce molecular alterations for IM, such as H. pylori infection
(Uemura et al., 2001), also induce molecular alterations for gas-
tric cancers.
Diagnosis of gastric cancers
Most patients with gastric cancer are diagnosed when they
undergo endoscopy and biopsy after exhibiting symptoms. In
Japan, about 25% of patients are diagnosed by mass screening
or a personal health check (Japanese National Gastric Cancer
Registry). In high-risk areas of this disease, the most important
issue is the education of general practitioners and the public to
make them aware of the risk of this cancer. Early diagnosis
used to be made by a barium meal study, especially in mass
screening in Japan (Oshima, 1997). Endoscopy is being used
more and more for secondary prevention in combination with a
serum test of pepsinogen subtypes. However, there is a con-
sensus that the efficacy of mass screening itself should be
reevaluated (Tsubono and Hisamichi, 2000).
At an early phase of development, a well-differentiated car-
cinoma (WDC) replaces the mucosa of atrophic gastritis or IM
without showing any invasion. As tumors progress, they start to
invade the lamina propria mucosae or the muscularis mucosae,
then the submucosal layer. As these invasive parts are often
missed by biopsy, the lesions are often diagnosed as dysplasia.
Thus, many lesions initially diagnosed as severe dysplasia
turned out to be an invasive cancer, sometimes invading even
the muscularis propria, after histological evaluation of resected
materials (Fertitta et al., 1993).
Diagnostic criteria for early gastric cancers and
endoscopic mucosal resection
Diagnostic criteria of WDC differs to some extent between the
West and the East (Schlemper et al., 1997). In Western coun-
tries, the diagnosis of adenocarcinoma is made only when
pathologists can recognize the evidence of invasion, while the
term cancer is used in the East when cellular or structural atyp-
ia is evident, even without evidence of invasion.WHO classifica-
tion now clearly states that the lesions called severe
dysplasia/adenoma in the West are the same as noninvasive
mucosal carcinoma in the East, and this is a result of patholo-
gists’ mutual communication and cooperation (Fenoglio-Preiser
et al., 1997). The Western policy runs the risk of overlooking
true cancers, but the Eastern policy may induce overtreatment.
However, as the result of the development of the technique of
endoscopic mucosal resection (EMR), the majority of such
lesions are now treated endoscopically in Japan (Ono et al.,
2001).Thus, paradoxically, “severe dysplasia” is often treated by
surgery in the West, and “noninvasive mucosal carcinoma” is
treated by EMR. This treatment can be applied exclusively to
mucosal cancer, for which endoscopic ultrasound (EUS) is
sometimes helpful. Because the histology of the entire speci-
men resected using EMR can be examined in detail, additional
surgery can be applied without much delay if a patient’s tumor is
found to have submucosal invasion. Because of these potential
advantages, distribution of the EMR technique to the West is
urgently needed.
Metastases and their diagnosis
Gastric cancer remains a localized disease for a long time and
metastasizes slowly. Table 2 shows the incidence of metastasis
to lymph nodes, the liver, and the peritoneum according to
tumor depth. Metastasis to sites other than these three sites is
rare. Systemic metastasis seldom occurs until the late phase of
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Table 1. Histology and genetic alterations of gastric cancers
Diffuse type (%) Intestinal type(%)
Oncogene activation
β-catenin 0 1727
K-ras 06 018
c-erbB2 1213 1213
Inactivation of tumor suppressor genes
p53 021 3643
APC 05 0
E-cadherin
Mutation 3350 0
Methylation 79 55
p16
Mutation 0 0
Methylation 11* 50*
Microsatellite instability 532 2341
*Incidences are overestimated due to analysis of CpG islands in exons.
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local invasion (T3/4). By deeper invasion, nodal metastasis
occurs more massively and to more distant areas. Nearly 20%
of T2 tumors have metastasis at the second tier nodes.
Systemic and local recurrences of T1/T2 lesions are rare when
treated by proper lymph node dissection, while local recurrence
is frequent after limited surgery (Sasako, 2003).
Conventional CT scanning is useful in detecting enlarged
nodes, which are often irresectable. However, 25% of metastatic
nodes are 5 mm or less and undetectable by any imaging diag-
nostic tool, including MRI, PET scan, or EUS (Noda et al., 1998).
Treatment of gastric cancers and its recent advances
Tumors without distant metastasis are potentially curable, and
treatment comprises resection of the primary tumor and control
of lymph node metastasis. For differentiated-type T1 mucosal
cancers, EMR is often successful, as metastasis does not gen-
erally occur (Gotoda et al., 2000).The Japanese Gastric Cancer
Treatment Guideline indicates the criteria for EMR as follows:
mucosal cancer of intestinal type, no ulcer nor ulcer scar in the
lesion, and size smaller than 21 mm (Nakajima, 2002). For more
advanced lesions, gastrectomy of over 2/3 of the stomach with
proper lymph node dissection is regarded as standard treat-
ment even in the West (Sasako, 2003; Allum et al., 2002; NCCN
Guideline [http://www.nccn.com/physician_gls/f_guidelines.html]),
in spite of the negative results of two large randomized trials
(Bonenkamp et al., 1999; Cuschieri et al., 1999).
Tumors with distant metastasis are mostly incurable at pre-
sent, with the rare exceptions of those with solitary liver metas-
tasis or peritoneal nodules. For these advanced or recurrent
tumors, chemotherapy shows a modest effect, and cure by
medical treatment is rare, even in combination with radiothera-
py. Combination chemotherapy using 5-fluorouracil with other
agents remains the most popular regimen.
Chemoradiotherapy and D2 surgery
Recently, chemoradiotherapy (CRT) after a potentially curative
operation was shown to improve the results of surgery without
lymph node dissection (MacDonald et al., 2001). As adjuvant
chemotherapy has not proven its efficacy over surgery alone,
these results strongly suggest the efficacy of radiotherapy to
achieve good local control. However, the results achieved by lim-
ited surgery followed by CRT are still worse than those of
extended surgery, so-called D2 nodal dissection. Currently,
questions regarding whether CRT in combination with limited
surgery can replace D2 surgery and whether CRT can improve
the results of D2 surgery alone remain to be answered. The for-
mer should be evaluated in the Western specialized centers,
where D2 surgery can be carried out safely with sufficient quality.
If this proves the efficacy of CRT, both questions should be
investigated in Japan. Meta-analysis evaluating the effect of
adjuvant chemotherapy without irradiation after curative surgery
for gastric cancer suggested strongly the effect of the treatment.
As none of the large sized trials has proven the effect of adjuvant
chemotherapy, it is urgent to establish standard adjuvant treat-
ment. At the moment, a large randomized trial is going on using
TS-1, which showed the highest response rate as a single agent
in the past. In Western countries, neoadjuvant chemotherapy for
advanced gastric cancer is now being tested in a few large
phase III trials. Neoadjuvant CRT is just now under investigation
as a phase II trial in some American institutions.
New chemotherapeutic agent
Some new chemotherapeutic agents, such as Irrinotecan, TS-1,
and Docetaxel, show promise as being more effective than con-
ventional drugs. A combination chemotherapy including TS-1 has
shown a response rate of over 70% (Koizumi et al., 2003). Further
studies may change the chemotherapy for gastric cancer.
Future challenges
Severe dysplasia/noninvasive mucosal carcinoma could con-
tain different entities that have different abilities to invade the
lamina propria mucosae. However, key molecular alterations
that determine this progression are unknown. The presence of
lymph node or distant metastasis is a very important factor in
deciding a treatment strategy, but accurate diagnosis is still dif-
ficult. Clarification of molecular alterations that are closely
linked with these characteristics will be beneficial to decide on a
treatment strategy for individual cases. Popular use of EMR
raises a new question, whether or not a secondary cancer will
arise from the remnant stomach, and prediction of risk for devel-
oping gastric cancer is becoming more important. Recent
genomic approaches demonstrate great potential for address-
ing these issues (Hasegawa et al., 2002). The more important
and appropriate questions we ask, the more useful these new
approaches will be.
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